Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 150.87
ARWR's Cash to Debt is ranked higher than
79% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. ARWR: 150.87 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 150.87

Equity to Asset 0.95
ARWR's Equity to Asset is ranked higher than
97% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ARWR: 0.95 )
ARWR' s 10-Year Equity to Asset Range
Min: -39.56   Max: 0.95
Current: 0.95

-39.56
0.95
F-Score: 4
Z-Score: 45.10
M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -22113.64
ARWR's Operating margin (%) is ranked lower than
51% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. ARWR: -22113.64 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -40
Current: -22113.64

-70800
-40
Net-margin (%) -28347.73
ARWR's Net-margin (%) is ranked lower than
51% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. ARWR: -28347.73 )
ARWR' s 10-Year Net-margin (%) Range
Min: -14371.43   Max: 1602.7
Current: -28347.73

-14371.43
1602.7
ROE (%) -47.70
ARWR's ROE (%) is ranked higher than
66% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. ARWR: -47.70 )
ARWR' s 10-Year ROE (%) Range
Min: -225.02   Max: -28.66
Current: -47.7

-225.02
-28.66
ROA (%) -43.71
ARWR's ROA (%) is ranked higher than
63% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. ARWR: -43.71 )
ARWR' s 10-Year ROA (%) Range
Min: -447.27   Max: 705.95
Current: -43.71

-447.27
705.95
ROC (Joel Greenblatt) (%) -1114.80
ARWR's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. ARWR: -1114.80 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11843.37   Max: -75
Current: -1114.8

-11843.37
-75
EBITDA Growth (%) 3.40
ARWR's EBITDA Growth (%) is ranked higher than
83% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ARWR: 3.40 )
ARWR' s 10-Year EBITDA Growth (%) Range
Min: -56.3   Max: 190.5
Current: 3.4

-56.3
190.5
EPS Growth (%) 38.40
ARWR's EPS Growth (%) is ranked higher than
95% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. ARWR: 38.40 )
ARWR' s 10-Year EPS Growth (%) Range
Min: -75.1   Max: 162.1
Current: 38.4

-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Jim Simons 54,400 sh (New)
Steven Cohen 1,500,000 sh (New)
» More
Q1 2014

ARWR Guru Trades in Q1 2014

George Soros 44,200 sh (New)
Steven Cohen 2,740,000 sh (+82.67%)
Jim Simons Sold Out
» More
Q2 2014

ARWR Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$9.79 - $18.28 $ 15.0415%0
George Soros 2014-03-31 New Buy0.01%$9.92 - $26.57 $ 15.04-13%44200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.27
ARWR's P/B is ranked higher than
77% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. ARWR: 4.27 )
ARWR' s 10-Year P/B Range
Min: 1.43   Max: 75.56
Current: 4.27

1.43
75.56
EV-to-EBIT -16.08
ARWR's EV-to-EBIT is ranked higher than
60% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARWR: -16.08 )
ARWR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.08

Current Ratio 19.81
ARWR's Current Ratio is ranked higher than
96% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ARWR: 19.81 )
ARWR' s 10-Year Current Ratio Range
Min: 0.01   Max: 302.61
Current: 19.81

0.01
302.61
Quick Ratio 19.81
ARWR's Quick Ratio is ranked higher than
96% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. ARWR: 19.81 )
ARWR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 302.61
Current: 19.81

0.01
302.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.24
ARWR's Price/Net Cash is ranked higher than
91% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 80.40 vs. ARWR: 5.24 )
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05   Max: 103.64
Current: 5.24

0.05
103.64
Price/Net Current Asset Value 5.24
ARWR's Price/Net Current Asset Value is ranked higher than
90% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 41.80 vs. ARWR: 5.24 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.05   Max: 95
Current: 5.24

0.05
95
Price/Tangible Book 4.35
ARWR's Price/Tangible Book is ranked higher than
83% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. ARWR: 4.35 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04   Max: 54.5
Current: 4.35

0.04
54.5
Forward Rate of Return (Yacktman) -23.00
ARWR's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. ARWR: -23.00 )
ARWR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -60   Max: -7.5
Current: -23

-60
-7.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany
Arrowhead Research Corp. was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a development stage nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. By working closely with scientists and universities, Arrowhead identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is focusing on developing and advancing a portfolio of subsidiaries in the field of nanomedicine. Arrowhead owns two majority-owned operating subsidiaries, Calando Pharmaceuticals and Unidym, Inc. and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc. Arrowhead also owns two nonoperating subsidiaries, Agonn Systems, Inc. and Tego Biosciences Corporation. Arrowhead's strategy is to maintain or build a majority ownership position in each portfolio company, thus providing significant exposure to their growth. Arrowhead's ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 
Arrowhead Reports First Quarter Fiscal 2009 Financial Results Feb 09 2009 

More From Other Websites
Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global... Sep 30 2014
Arrowhead to Present at BioCentury’s NewsMakers in the Biotech Industry Conference Sep 19 2014
3 Biotech Breakout Charts That Could See More Upside Next Week Sep 11 2014
Arrowhead Research Corp Heads Higher After Breakout Sep 04 2014
Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD Sep 03 2014
Arrowhead Research Corp Shares Push Over Resistance Level As Momentum Continues Sep 03 2014
Winners & Losers From Tuesday, August 26 Aug 26 2014
Arrowhead Research (ARWR) Stock Rises on High Volume Aug 26 2014
[video] $8.3 billion biotech deal Aug 25 2014
ARROWHEAD RESEARCH CORP Financials Aug 19 2014
ARWR: Arrowhead Reported Fiscal 2014 Third Quarter Financial Results with a Strong Balance Sheet Aug 18 2014
Arrowhead Discloses First Human Hepatitis B Therapy Results Aug 12 2014
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 12 2014
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 Aug 12 2014
ARROWHEAD RESEARCH CORP Files SEC form 10-Q, Quarterly Report Aug 12 2014
Q3 2014 ARROWHEAD RESH CORP Earnings Release - After Market Close Aug 12 2014
Today's Dead Cat Bounce Stock Is Arrowhead Research (ARWR) Aug 04 2014
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results Jul 31 2014
Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock Jul 31 2014
'Fast Money' Recap: Playing China Through U.S. Stocks Jul 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK